MMSL 2023, 92(2):184-190 | DOI: 10.31482/mmsl.2023.016

HYPERLIPIDEMIA CONNOTED VITIATION OF SERUM ADIPOKINES AND REDOX IMBALANCESOriginal article

Jehan A. Mohammad ORCID..., Fatimah Haitham Fathi ORCID...*, Ammar A.Y. Almulathanon ORCID..., Marwan M. Merkhan ORCID...
College of Pharmacy, University of Mosul, Mosul, Iraq

Background and objectives: Atherosclerosis is the underlying pathology of ischemic heart disease. There are many aggravating metabolic and oxidant parameters which are participating together overwhelming the pathology of vascular stenosis. Adipokines play a positive metabolic effect in healthy individuals and oxidation reaction greatly impacts the lipid metabolism and might negatively impact the condition. In the present study, we aimed to characterize the level of adiponectin, obestatin, and redox parameters in atherosclerotic patients.

Methods: Serum was collected from atherosclerotic patients and froze to be ready for analysis.

Results: The results indicated that hyperlipidemia significantly reduced adiponectin, obestatin, and antioxidant enzymes (catalase, glutathione, glutathione-S-transferase, and glutathione peroxidase) together with a significant increase in oxidant byproduct (malondialdehyde) and modulated lipid parameters (cholesterol, triglyceride, and high-density lipoprotein).

Conclusion: The study concluded that atherosclerosis is associated with reduced antioxidant enzymes, obestatin, and adiponectin levels and increased lipid levels. These parameters play a great role in the patho-logical status of coronary stenosis.

Keywords: Adipokines; Adiponectin; Antioxidant enzymes; Hyperlipidemia; Obestatin

Received: January 7, 2023; Revised: April 12, 2023; Accepted: April 12, 2023; Prepublished online: April 17, 2023; Published: June 2, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mohammad, J.A., Fathi, F.H., Almulathanon, A.A.Y., & Merkhan, M.M. (2023). HYPERLIPIDEMIA CONNOTED VITIATION OF SERUM ADIPOKINES AND REDOX IMBALANCES. MMSL, 92(2), 184-190. doi: 10.31482/mmsl.2023.016
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Hormone and Metabolic Research. 2000;32(02),47-50. Go to original source... Go to PubMed...
    2. Ekmekci H, Ekmekci OB. The role of adiponectin in atherosclerosis and thrombosis. Clinical and applied thrombosis/hemostasis. 2006;12(2),163-168. Go to original source... Go to PubMed...
    3. Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase-1 activity, atherosclerotic burden, and cardiovascular prognosis. The American journal of cardiology. 2007;99(6):808-812. Go to original source... Go to PubMed...
    4. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(1):29-33. Go to original source... Go to PubMed...
    5. Haendeler J, Eckers A, Lukosz M, et al. Endothelial NADPH oxidase 2: when does it matter in atherosclerosis?. Cardiovascular research. 2012;94(1):1-2. Go to original source... Go to PubMed...
    6. Lip GYH, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? Journal of internal medicine. 2001;249(3):205-214. Go to original source... Go to PubMed...
    7. Buijsse B, Lee DH, Steffen L, et al. Low serum glutathione peroxidase activity is associated with increased cardiovascular mortality in individuals with low HDLc's. PloS one. 2012;7(6), p.e38901. Go to original source... Go to PubMed...
    8. Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis. 2014;233(2):721-728. Go to original source... Go to PubMed...
    9. Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocrine, Metabolic & Immune Disorders-Drug Targets. 2012;12(2):118-131. Go to original source... Go to PubMed...
    10. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 2002;51(7):2325-2328. Go to original source... Go to PubMed...
    11. Zainab H. Fathi, Jehan A. Mohammad, Marwah H. Mohammed. Evaluation of the Vasoprotective Effects of Metformin versus Glibenclamide in Type 2 Diabetic Patients. Research Journal of Pharmacy and Technology. 2021;14(12):6409-6412. Go to original source...
    12. Hopkins TA, Ouchi N, Shibata R, et al. Adiponectin actions in the cardiovascular system. Cardiovascular research. 2007;74(1):11-18. Go to original source... Go to PubMed...
    13. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Medical molecular morphology. 2007;40(2):55-67. Go to original source... Go to PubMed...
    14. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-2476. Go to original source... Go to PubMed...
    15. Lee, B, Shao J. Adiponectin and lipid metabolism in skeletal muscle. Acta Pharmaceutica Sinica B. 2012;2(4):335-340. Go to original source...
    16. Gu PY, Kang DM, Wang WD, et al. Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus. Journal of diabetes research. 2013; 2013. Go to original source... Go to PubMed...
    17. Fathi ZH, Mohammad JA, Younus ZM, et al. Hepcidin as a Potential Biomarker for the Diagnosis of Anemia. Turk J Pharm Sci. 2022;19(5):603-609. Go to original source... Go to PubMed...
    18. Çelik N, Cinaz P, Bideci A, et al. Endoglin and obestatin levels, cardiometabolic risk factors and subclinical atherosclerosis in children aged 10-18 years. Journal of Pediatric Endocrinology and Metabolism. 2016;29(10):1173-1180. Go to original source... Go to PubMed...
    19. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. International journal of molecular sciences. 2017;18(6):1321. Go to original source... Go to PubMed...
    20. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clinica chimica acta. 2004;344(1-2):1-12. Go to original source... Go to PubMed...
    21. Golley RK, Maher CA, Matricciani L, et al. Sleep duration or bedtime? Exploring the association between sleep timing behaviour, diet and BMI in children and adolescents. International journal of obesity. 2013;37(4):546-551. Go to original source... Go to PubMed...
    22. Liu, M, Liu F. Regulation of adiponectin multimerization, signaling and function. Best practice & research Clinical endocrinology & metabolism. 2014;28(1):25-31. Go to original source... Go to PubMed...
    23. Ohashi K, Ouchi N, et al. 2012. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2014;94(10):2137-2142. Go to original source... Go to PubMed...
    24. Letra L, Sena C. 2017. Cerebrovascular disease: consequences of obesity-induced endothelial dysfunction. Obesity and Brain Function, 163-189. Go to original source...
    25. Primeaux SD, Tong M, Holmes GM. Effects of chronic spinal cord injury on body weight and body composition in rats fed a standard chow diet. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2007;293(3):1102-1109. Go to original source... Go to PubMed...
    26. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature medicine. 2002;8(7):731-737. Go to original source... Go to PubMed...
    27. Kim MJ, Yoo KH, Park HS, et al. Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus. Yonsei medical journal. 2005;46(1):42-50. Go to original source... Go to PubMed...
    28. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004;84(4):1381-1478. Go to original source... Go to PubMed...
    29. Condell RA, Tappel AL. Evidence for suitability of glutathione peroxidase as a protective enzyme: studies of oxidative damage, restoration and proteolysis. Arch. Biochem. Biophys. 1983;223(2):407-416. Go to original source... Go to PubMed...
    30. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. Journal of Biological Chemistry. 2006;281(5):2654-2660. Go to original source... Go to PubMed...
    31. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. Journal of Biological Chemistry. 2002;277(40):37487-37491. Go to original source... Go to PubMed...
    32. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767-2770. Go to original source... Go to PubMed...

    Return to the content